Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Core Viewpoint - Matinas BioPharma Holdings, Inc. has appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025, enhancing the company's governance and financial oversight capabilities [1][2]. Company Overview - Matinas BioPharma is a biopharmaceutical company focused on delivering innovative therapies through its lipid nanocrystal (LNC) platform delivery technology [3]. Appointment Details - Evelyn D'An brings extensive experience in corporate governance, financial oversight, and accounting, having served as Chair of Audit Committees for various public and private companies [2]. - D'An is a former partner at Ernst & Young, where she spent 18 years working with clients across multiple sectors, including retail and technology [2]. Leadership Commentary - Jerome D. Jabbour, CEO of Matinas, expressed enthusiasm about D'An's appointment, highlighting her strategic expertise and the importance of her role at this critical time for the company [3].